Abstract: The present invention discloses methods of inhibiting biofilm formation, increasing bacteriocidal activity within a biofilm, treating bacteria within a biofilm, or remediating a biofilm in or on a subject, comprising administering to the subject an effective amount of a compound according to Formula I: wherein R1-5 are defined herein.

Abstract: Disclosed are compositions and methods for stimulating immune responses. More particularly, these compositions and methods involve the use of an inhibitor of IL-25 function and an immune stimulator that stimulates an immune response to a target antigen for stimulating protective or therapeutic immune responses to a target antigen. The compositions and methods of the present invention are particularly useful in the prevention and treatment of infections and cancers.

Abstract: The presently disclosed invention relates to devices and methods for conducting bone surgery on an animal using a bone surgery tool comprising a base, a fixed arm fixed to the base, the fixed arm including a shoulder and a jaw, a sliding arm releasably fixable to the base, the sliding arm including a head that receives an implant and a cartridge in a slot, the method comprising hooking the bone with the jaw, moving the head toward the jaw capturing the bone, accessing the bone with a drill through cartridge bores in the cartridge, and drilling holes, accessing the bone with a self-shearing screw attached to a screw driver through cartridge bores in the cartridge, and attaching the implant to the bone, and moving the head away from the jaw releasing the bone.

Abstract: A device, system and method for creating pulsed electric fields with good uniformity are provided. The electric fields occupy a large volume, suitable for placing a human or animal patient. A device for generating the electric fields is provided, which comprises one or more toroidally or cylindrically shaped magnetic core(s) wound with electrical wires, which, when pulsed with electrical currents, generate an electric field of high uniformity in the interior region of the toroidal or cylindrical cores. These electric field pulses, when used in conjunction with pharmacological agent, destroy cancer cells through a process called Targeted Osmotic Lysis.

Abstract: Engineered Cementitious Composites (ECC) and cement products including Engineered Cementitious Composites are provided. The ECC can include cement, sugar cane bagasse ash, and fiber. The sugar cane bagasse ash can be processed to provide a partial cement or sand replacement in ECCs and cement products.

Abstract: An electro-acupuncture (EA) system and method for performing EA on a patient are provided. The EA system comprises a wearable neurostimulator device, at least a first pair of electrically-conductive acupuncture needles and a system controller. The wearable neurostimulator device comprises a casing, an EA circuit mechanically coupled to the casing, and an attachment device mechanically coupled to the casing and adapted to removably secure the wearable neurostimulator device to the patient. The first pair of electrically-conductive acupuncture needles is mechanically coupled to the casing and electrically coupled to the EA circuit. The system controller is in communication with the EA circuit of the wearable neurostimulator device via a communication link and controls the EA circuit to cause the EA circuit to output an output voltage selected by the system controller at a frequency selected by the system controller.

Abstract: Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.

Abstract: The application describes recombinant BoHV-1 triple mutant viruses that express protective antigens of other bovine respiratory viruses associated with Bovine respiratory disease complex (BRDC).

Abstract: A conditionally replicating adenovirus were generated that can specifically replicate and express therapeutic genes in neuroendocrine tumors. The promoter-specific expression of the adenoviruses is regulated upstream by an INSM1 (insulinoma-associated-1) promoter that is silent in normal adult tissues but active in developing neuroendocrine cells and neuroendocrine tumors. By placing the I NSM 1-promoter with an insulator and two copies of neuronal restrictive silencer elements in an adenoviral vector, the construct can retain tumor specificity and drive expression of a mutated adenovirus E1A gene (?24E1A) and the herpes simplex virus thymidine kinase gene. The I NSM1-promoter-driven viruses could replicate specifically in the I NSM1-positive cells and I NSM1-specific HSV-tk expression in combination with ganciclovir treatment displayed dose-dependent tumor cell-specific killing in insulinomas.

Abstract: A genetically modified non-human animal comprising a genome containing an endogenous non-human ACE2 locus genetically modified to encode a complete human ACE2 gene. According to a further embodiment the genome is genetically modified to encode a second, a third, and a fourth complete human ACE2 gene, the human ACE2 gene is at least 85 percent identical to SEQ ID No: 1, the animal of is a mouse, the human ACE2 gene encodes six protein variants, an endogenous Tmprss2 gene is unmodified, a LoxP gene flanks each of a 5? and a 3? end of a nucleic acid sequence of the human ACE2 gene, and the human ACE2 gene is expressed in a lung, kidney, spleen, stomach, liver, intestine, heart, and skeletal muscle of the animal, and a cortex, striatum, middle brain, hippocampus, olfactory bulb, and cerebellum of a brain of the animal.

Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, dially disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.

Abstract: Glycosaminoglycans, particularly hyaluronic acid, are extracted from alligator carcasses, feet, backstraps, and eyeballs. The alligator-derived glycosaminoglycans can be used in treatments for cystic fibrosis (CF), in treating other inflammatory conditions, and for other purposes.

Abstract: Therapeutics and methods for treating a stroke in a human comprising administering a therapeutic to the patient, wherein the therapeutic comprises one of immortalized human placenta mesenchymal stem cells (hPMSCs) and a product from the immortalized hPMSCs. Methods and therapeutic products comprising extracellular vesicles (EVs) isolated from of immortalized hPMSCs. Therapeutics and methods of treating COVID-19 disease vascular injury comprising administering a therapeutic to the patient, wherein the therapeutic comprises one of hPMSCs and a product from the hPMSCs.

Abstract: An automatic door handle/panel sanitizer dispensing assembly comprising a frame, a control unit including a processor, an actuator assembly controlled by the processor, the actuator assembly includes one of a pump and a valve, a first sensor operatively connected to the processor, a power storage unit powering the control unit, the actuator assembly, and the first sensor, a first nozzle and a second nozzle, both fluidly connected to the actuator assembly, a container coupled to the frame, for storing disinfectant, a threaded hook to hang the assembly onto the door handle, a tray having an arcuate shape and being arranged abutting a roof of the frame and being supported by the frame, a plurality of threaded tray holes extending through the tray arranged proximate to a rear end of the tray.

Abstract: Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.

Abstract: The present invention provides compositions, methods and kits for the temporal control induction time for a polymerization reaction.

Abstract: A device and method are disclosed for intravenous cannulation. The device employs a spring to precisely and accurately control the force and velocity imparted to a piercing needle, with mechanical constraints built into the device to precisely and accurately control the distance through which the piercing needle travels. A sheathed-needle configuration is used with an outer, echogenic needle that can be seen via ultrasound; and an inner needle used to pierce the vein. The operator releases the piercing needle with a controlled velocity, controlled force, and controlled travel distance. The device reduces the human error and complications that have previously been associated with manually piercing a vein for cannulation.

Abstract: A mouthwash for fluorescence endoscopic dental imaging includes at least one fluorescent dye and a liquid base. A method for fluorescent endoscopic dental imaging includes orally administering a mouthwash to a subject; waiting a predetermined period of time; removing excess mouthwash from the subject; illuminating the subject with visible or near-infrared light; and capturing fluorescent light from the subject to create an image.

Abstract: Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutical composition containing a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains both an ACE2 externalizer and one or more ACE2 internalization preventors. Methods of treatment and pharmaceutical compositions comprising an ACE2 externalizer and one or more ACE2 internalization preventors.